ENLIVEN THERAPEUTICS, INC. (ELVN)

SEC filing

ENLIVEN THERAPEUTICS, INC.

ELVN · CIK 1672619

4 · Oct 21, 2026 · CHIEF FINANCIAL OFFICER Hohl Benjamin sold 6,018 shares at $38.48/share ($231.5K); exercised options for 12.04K shares

CHIEF FINANCIAL OFFICER Hohl Benjamin sold 6,018 shares at $38.48/share ($231.5K); exercised options for 12.04K shares

xslF345X06/form4-10212026_091038.xml

xslF345X06/form4-10212026_091038.xmlSEC.gov

Graphics and non-inline formats (not embedded below).